Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | IDO1 | P14902 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.76 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686124 | 0.91 | TRPV1 (0.84) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL25137286 | 0.88 | TRPV1 (0.76) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL2271234 | 0.88 | SPR (0.74) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL31036202 | 0.88 | TRPV1 (0.91) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL13996187 | 0.87 | SPR (0.73) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL17211923 | 0.87 | MTNR1A (0.76) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL6425731 | 0.87 | SPR (0.72) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL6424921 | 0.87 | SPR (0.72) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| SCHEMBL12720729 | 0.87 | SPR (1.00) | SPRKDM4EALDH1A1CYP2D6NPSR1 | |
| Acetylserotonin SCHEMBL30295379 | 0.86 | SPR (1.00) | SPRKDM4EALDH1A1CYP2D6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303617-B1 | FOR THERAPY OF OBESITY, LOWERING SERUM CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN IN MAMMALS, INHIBITOR OF MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-16 | — | — | US | claimed |
| EP-2282735-B1 | PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES | SIGNUM BIOSCIENCES INC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| CN-1727339-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-01 | — | — | CN | disclosed |
| EP-1550655-A1 | Bicyclic intermediates | Takeda Pharmaceutical Company Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| CN-1212691-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-03-31 | — | — | CN | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
| US-4908322-A | Reacting sample with O-acyl N-hydroxysulfosuccinamide to form N-acylated amine derivative, separating, chromatographically analyzing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SPR, QDPR, SRR | SPR 1/4885KDM4E 3528/4885ALDH1A1 788/4885 |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | SPR 4166/4885KDM4E 2945/4885ALDH1A1 3993/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | SPR 4166/4885KDM4E 2945/4885ALDH1A1 3993/4885 |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | PPP2CA, PPP4C, PPP6C | SPR 1640/4885KDM4E 243/4885ALDH1A1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.